Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Clinical Colorectal Cancer
|
June 12, 2012
Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study
Olivier Capitain, Andreaa Asevoaia, Michele Boisdron-Celle, et al.
Cancer Letters
|
January 3, 2006
Tumor quantification of several fluoropyrimidines resistance gene expression with a unique quantitative RT-PCR method. Implications for pretherapeutic determination of tumor resistance phenotype
Maud Barbado, Laurence Preisser, Michele Boisdron-Celle, et al.
Molecular Cancer Therapeutics
|
November 24, 2006
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance
Alain Morel, Michele Boisdron-Celle, Luc Fey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2004
Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer
Laurence Gamelin, Michele Boisdron-Celle, Remy Delva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2007
Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway
Laurence Gamelin, Olivier Capitain, Alain Morel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2008
Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer
Erick Gamelin, Remy Delva, Jacques Jacob, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery
|
June 4, 2008
Aerosolized chemotherapy
Frederic Gagnadoux, Jose Hureaux, Laurent Vecellio, et al.
Seminars in Oncology
|
September 20, 2017
In reply
Michele Boisdron-Celle, Olivier Capitain, Roger Faroux, et al.
Seminars in Oncology
|
April 12, 2017
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach
Michele Boisdron-Celle, Olivier Capitain, Roger Faroux, et al.
Cancer Chemotherapy and Pharmacology
|
February 15, 2025
Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial)
Maarten A Hanrath, Evi Banken, Sebastian A H van den Wildenberg, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Clinical Colorectal Cancer
|
June 12, 2012
Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study
Olivier Capitain, Andreaa Asevoaia, Michele Boisdron-Celle, et al.
Cancer Letters
|
January 3, 2006
Tumor quantification of several fluoropyrimidines resistance gene expression with a unique quantitative RT-PCR method. Implications for pretherapeutic determination of tumor resistance phenotype
Maud Barbado, Laurence Preisser, Michele Boisdron-Celle, et al.
Molecular Cancer Therapeutics
|
November 24, 2006
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance
Alain Morel, Michele Boisdron-Celle, Luc Fey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2004
Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer
Laurence Gamelin, Michele Boisdron-Celle, Remy Delva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2007
Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway
Laurence Gamelin, Olivier Capitain, Alain Morel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2008
Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer
Erick Gamelin, Remy Delva, Jacques Jacob, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery
|
June 4, 2008
Aerosolized chemotherapy
Frederic Gagnadoux, Jose Hureaux, Laurent Vecellio, et al.
Seminars in Oncology
|
September 20, 2017
In reply
Michele Boisdron-Celle, Olivier Capitain, Roger Faroux, et al.
Seminars in Oncology
|
April 12, 2017
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach
Michele Boisdron-Celle, Olivier Capitain, Roger Faroux, et al.
Cancer Chemotherapy and Pharmacology
|
February 15, 2025
Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial)
Maarten A Hanrath, Evi Banken, Sebastian A H van den Wildenberg, et al.
Page
of 1